You just read:

Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx

News provided by

Isis Pharmaceuticals, Inc.

Mar 07, 2012, 08:00 ET